Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 18/20 | 0.65 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13596147 | 0.87 | CACNA1H (0.70) | CACNA1HKIT | |
| SCHEMBL12877006 | 0.83 | CACNA1H (0.72) | CACNA1HKITGRIN2B | |
| SCHEMBL8212405 | 0.79 | CACNA1H (0.71) | CACNA1H | |
| SCHEMBL12876984 | 0.79 | CACNA1H (0.71) | CACNA1H | |
| SCHEMBL8217756 | 0.78 | CACNA1H (0.59) | CACNA1HKIT | |
| SCHEMBL12877017 | 0.77 | CACNA1H (0.78) | CACNA1H | |
| SCHEMBL8225775 | 0.76 | CACNA1H (0.83) | CACNA1H | |
| SCHEMBL8224871 | 0.76 | CACNA1H (0.62) | CACNA1H | |
| SCHEMBL8202156 | 0.76 | CACNA1H (1.00) | CACNA1H | |
| SCHEMBL8214077 | 0.76 | CACNA1H (1.00) | CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-7638526-B2 | Azetidine derivatives useful in treating pain, diabetes and disorders of lipid metabolism | SCHERING CORPORATION (US) | 2009-12-29 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | SCHERING CORPORATION | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080089858-A1 | AZETIDINE DERIVATIVES USEFUL IN TREATING PAIN, DIABETES AND DISORDERS OF LIPID METABOLISM | GPR119, PNLIP, CYP46A1 | CACNA1H 1192/4885KIT 1423/4885GRIN2B 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.